The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The immunotherapeutic potential of melatonin
Abstract
The interaction between the brain and the immune system is essential for the adaptive response of an organism against environmental challenges. In this context, the pineal neurohormone melatonin (MEL) plays an important role. T-helper cells express G-protein coupled cell membrane MEL receptors and, perhaps, MEL nuclear receptors. Activation of MEL receptors enhances the release of T-helper cell Type 1 (Th1) cytokines, such as gamma-interferon (gamma-IFN) and IL-2, as well as of novel opioid cytokines. MEL has been reported also to enhance the production of IL-1, IL-6 and IL-12 in human monocytes. These mediators may counteract stress-induced immunodepression and other secondary immunodeficiencies and protect mice against lethal viral encephalitis, bacterial diseases and septic shock. Therefore, MEL has interesting immunotherapeutic potential in both viral and bacterial infections. MEL may also influence haemopoiesis either by stimulating haemopoietic cytokines, including opioids, or by directly affecting specific progenitor cells such as pre-B cells, monocytes and NK cells. MEL may thus be used to stimulate the immune response during viral and bacterial infections as well as to strengthen the immune reactivity as a prophylactic procedure. In both mice and cancer patients, the haemopoietic effect of MEL may diminish the toxicity associated with common chemotherapeutic protocols. Through its pro-inflammatory action, MEL may play an adverse role in autoimmune diseases. Rheumatoid arthritis patients have increased nocturnal plasma levels of MEL and their synovial macrophages respond to MEL with an increased production of IL-12 and nitric oxide (NO). In these patients, inhibition of MEL synthesis or use of MEL antagonists might have a therapeutic effect. In other diseases such as multiple sclerosis the role of MEL is controversial. However, the correct therapeutic use of MEL or MEL antagonists should be based on a complete understanding of their mechanism of action. It is not yet clear whether MEL acts only on Th1 cells or also on T-helper Type 2 cells (Th2). This is an important point as the Th1/Th2 balance is of crucial importance in the immune system homeostasis. Furthermore, MEL being the endocrine messenger of darkness, its endogenous synthesis depends on the photoperiod and shows seasonal variations. Similarly, the pharmacological effects of MEL might also be season-dependent. No information is available concerning this point. Therefore, studies are needed to investigate whether the immunotherapeutic effect of MEL changes with the alternating seasons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ISOLATION OF MELATONIN, THE PINEAL GLAND FACTOR THAT LIGHTENS MELANOCYTES1
Lerner, A. B., Case, J. D., Takahashi, Y., Lee, T. H., & Mori, W. (1958) · Journal of the American Chemical Society · doi:10.1021/ja01543a060 · Cited by 1,758
Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease
Elenkov, I. J., & Chrousos, G. P. (1999) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(99)00188-5 · Cited by 804
Psychoneuroimmunology: interactions between the nervous system and the immune system
Ader, R., Cohen, N., & Felten, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90066-7 · Cited by 802
West Nile encephalitis epidemic in southeastern Romania
Tsai, T., Popovici, F., Cernescu, C., Campbell, G., & Nedelcu, N. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03538-7 · Cited by 756
Cellular Mechanisms of Melatonin Action
VANECEK, J. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.3.687 · Cited by 578
Evidence for melatonin synthesis in mouse and human bone marrow cells
Conti, A., Conconi, S., Hertens, E., Skwarlo‐Sonta, K., Markowska, M., & Maestroni, G. J. M. (2000) · Journal of Pineal Research · doi:10.1034/j.1600-079x.2000.280401.x · Cited by 379
Self-citationIdentification of highly elevated levels of melatonin in bone marrow: its origin and significance
Tan, D.-X., Manchester, L. C., Reiter, R. J., Qi, W.-B., Zhang, M., Weintraub, S. T., Cabrera, J., Sainz, R. M., & Mayo, J. C. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00125-7 · Cited by 343
Seabra, M. D. L. V., Bignotto, M., Pinto Jr., L. R., & Tufik, S. (2000) · Journal of Pineal Research · doi:10.1034/j.1600-0633.2002.290401.x · Cited by 279
Gilad, E., Wong, H. R., Zingarelli, B., Virág, L., O'connor, M., Salzman, A. L., & Szabó, C. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.9.685 · Cited by 252
Cunha, F. Q., Assreuy, J., Moss, D. W., Rees, D. D., Leal, L. M. C. C., Moncada, S., CARRIER, M. J., O'Donnell, C. A., & Liew, F. Y. (1994) · PubMed Central · Cited by 192
Cited by
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875
Self-citationPhysiological effects of melatonin: Role of melatonin receptors and signal transduction pathways
PANDIPERUMAL, S., TRAKHT, I., SRINIVASAN, V, SPENCE, D., MAESTRONI, G., ZISAPEL, N., & CARDINALI, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.04.001 · Cited by 791
Self-citationSimonneaux, V., & Ribelayga, C. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.2 · Cited by 740
Melatonin: Buffering the Immune System
Carrillo-Vico, A., Lardone, P., Álvarez-Sánchez, N., Rodríguez-Rodríguez, A., & Guerrero, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048638 · Cited by 740
A Review of the Multiple Actions of Melatonin on the Immune System
Carrillo-Vico, A., Guerrero, J. M., Lardone, P. J., & Reiter, R. J. (2005) · Endocrine · doi:10.1385/endo:27:2:189 · Cited by 666
Metadata
- Authors
- Maestroni, G. J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2001-03
- Volume
- 10
- Issue
- 3
- Pages
- 467-476
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2067503520
- Cited by
- 253
- References
- 50
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The immunotherapeutic potential of melatonin. https://app.cochat.ai/papers/10.1517/13543784.10.3.467
- The paper
- Maestroni, G. J. (2001). The immunotherapeutic potential of melatonin. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.10.3.467
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.